Cluster Analysis of Tumor Suppressor Genes in Canine Leukocytes Identifies Activation State

Julie-Anne Daly*, Sally-Anne Mortlock*, Rosanne M. Taylor and Peter Williamson
Faculty of Veterinary Science, The University of Sydney, Camperdown, NSW, Australia. *Contributed equally to this study.

Supplementary Issue: Current Developments in Veterinary Bioinformatics

ABSTRACT: Cells of the immune system undergo activation and subsequent proliferation in the normal course of an immune response. Infrequently, the molecular and cellular events that underlie the mechanisms of proliferation are dysregulated and may lead to oncogenesis, leading to tumor formation. The most common forms of immunological cancers are lymphomas, which in dogs account for 8%–20% of all cancers, affecting up to 1.2% of the dog population. Key genes involved in negatively regulating proliferation of lymphocytes include a group classified as tumor suppressor genes (TSGs). These genes are also known to be associated with progression of lymphoma in humans, mice, and dogs and are potential candidates for pathological grading and diagnosis. The aim of the present study was to analyze TSG profiles in stimulated leukocytes from dogs to identify genes that discriminate an activated phenotype. A total of 554 TSGs and three gene set collections were analyzed from microarray data. Cluster analysis of three subsets of genes discriminated between stimulated and unstimulated cells. These included 20 most upregulated and downregulated TSGs, TSG in hallmark gene sets significantly enriched in active cells, and a selection of candidate TSGs, p15 (CDKN2B), p18 (CDKN2C), p19 (CDKN1A), p21 (CDKN2A), p27 (CDKN1B), and p53 (TP53) in the third set. Analysis of two subsets suggested that these genes or a subset of these genes may be used as a specialized PCR set for additional analysis.

KEYWORDS: canine, lymphoma, gene expression, microarray

SUPPLEMENT: Current Developments in Veterinary Bioinformatics

CITATION: Daly et al. Cluster Analysis of Tumor Suppressor Genes in Canine Leukocytes Identifies Activation State. Bioinformatics and Biology Insights 2015:9(S2) 59–67 doi: 10.4137/BBI.30523.

TYPE: Original Research

RECEIVED: July 23, 2015. RESUBMITTED: May 23, 2016. ACCEPTED FOR PUBLICATION: May 29, 2016.

ACADEMIC EDITOR: Thomas Dandekar, Associate Editor

PEER REVIEW: Seven peer reviewers contributed to the peer review report. Reviewers' reports totaled 1,516 words, excluding any confidential comments to the academic editor.

FUNDING: This study was funded by the Canine Research Foundation and by the Maple Simmons Canine Lymphoma bequest. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

CORRESPONDENCE: p.williamson@sydney.edu.au

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with all copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE). Published by Libertas Academica. Learn more about this journal.

Introduction

The application of genomics to medicine and pathology has moved very quickly in humans, particularly in cancer diagnosis and treatment. The use of gene expression signatures and identification of biomarkers, such as miRNAs, have been particularly valuable in dissecting cancer pathogenesis and pathological grading of cancer types.1–3 Similar developments in veterinary medicine are beginning to emerge, with progress informed by the experience in humans.4 One relatively common disease that has received attention is canine lymphoma. Although there are a number of subtypes with differing pathogeneses, many show characteristics of activated lymphocytes.

During their life cycle, lymphocytes undergo rapid periods of clonal expansion and contraction during ontogeny and differentiation as a result of activation-induced proliferation caused by invading pathogens. Proliferation requires the activation of up to 10,000 genes and a complex program of signal transduction and cell division. When the program of proliferation and regression is disturbed, cells may undergo oncogenic transformation, resulting in the development of lymphoma. Lymphoma is one of the most common cancers in dogs, accounting for up to 20.1% of cancers in male dogs and 8.4% in female dogs.5,6 Lymphoma can be classified into two distinct immunophenotypes, those of B-cell origin and those of T-cell origin, representing 67% and 31% of canine non-Hodgkin’s lymphoma cases, respectively.7 T-cell lymphomas proliferate at higher rates than B-cell lymphomas, making them an aggressive cancer with poor prognosis. They are also less responsive to treatment and do not respond well to a typical course of chemotherapy.8

The development of lymphoma is a complex process that results from accumulation of mutations that disrupt normal homeostatic mechanisms of cell cycle progression and apoptosis.9 Under normal circumstances, cell cycle progression is regulated by cyclins and phosphorylation states of key molecules controlled by cyclin–dependent kinases. There is also a major class of molecules that inhibit progression, providing what are referred to as checkpoints during transition from progressive stages of the cell cycle. Many of these molecules have also been characterized as tumor suppressors, reflecting the fact that oncogenesis can arise as a result of loss of function mutations in the genes that code for these proteins. Because these molecules function as negative regulators, the processes of
lymphocyte activation and maintenance of a proliferative state are sensitive to changes in tumor suppressor gene (TSG) expression levels.

The family of TSGs has gradually increased with further definition of the functional category that extends beyond cell cycle arrest to apoptosis and repair of damaged DNA. Furthermore, either changes to gene expression levels or functional mutations of TSGs can compromise regulatory checkpoints and increase the likelihood of uncontrolled cell proliferation. These changes may occur prior to, or after tumorigenesis, and have the potential to contribute to both lymphomagenesis and disease progression. Documented somatic changes in canine lymphoma include reduced expression of the tumor suppressor/cell cycle regulator protein, p16INK4A (CDKN2A), and mutations in the p53 (TP53) TSG. TSGs are potential markers for activated lymphocytes, and some have been shown to be useful in molecular diagnosis of lymphoma. Studies in dogs have focused on small numbers of individual TSG rather than larger scale expression profiles distinctive of an activated leukocyte phenotype.

We hypothesized that the levels of subsets of TSG expression may be good indicators of activated lymphocytes and may be useful as diagnostic or prognostic tools in canine lymphoma, similar to the use of gene expression profiles that have been used to discover and implement biomarkers in human lymphoproliferative disorders. Hence, the aim of the present study was to analyze expression profiles of canine TSGs in leukocytes to identify genes that discriminate between resting and activated states. The analysis focused on data from microarray analysis and annotation based on human and canine databases. Three gene set collections were also tested for enrichment with activated cells. Additional analysis focused on quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) for seven candidate genes known to be involved in control of cell cycle progression and with previous links to lymphoma.

Materials and Methods

Sample selection and RNA extraction. Samples included in the study were derived from 11 dogs, all Bullmastiffs ranging between eight months and seven years of age. The study was approved by the University of Sydney Animal Ethics Committee under protocol N00/3-2009/3/4949. RNA from each of the dogs was obtained from blood samples collected by a veterinarian. The leukocyte fraction from each sample was divided into two tubes, each resuspended in 1 mL of Dulbecco’s modified Eagle’s medium. Half the samples were then stimulated through the addition of 5 µg of phytohemagglutinin (PHA), as previously described. Briefly, total RNA was isolated from samples using a modified extraction procedure and microspin columns, according to manufacturer’s recommendations (QIAGen; Qiagen). Purified RNA was eluted in 30 µL of RNase-free water and stored at -80 °C.

Microarray analysis. Analysis of microarray data was performed as described previously. Briefly, background correction and quantile normalization were performed on the data with probe-set intensities calculated accordingly using the Robust Multichip Average algorithm available from the Affymetrix Expression Console Software. Differential expression (DE) of genes between stimulated and unstimulated T-cells was defined using the limma function (linear model approach) incorporated in the R package - oneChannelGUI. A rank fold change was used to identify DE genes, with a cut-off of ±2-fold, corresponding to a Benjamini and Hochberg adjusted false discovery rate (FDR) of 0.05.

Identification of TSGs. A list of TSGs was retrieved from database and literature sources. A total of 637 gene records were downloaded from TSGene. Each of the 637 genes was manually annotated for canine cancer and assessed against the probe sets relevant to Affymetrix Canine Genome Array ST. Further annotation was performed against the Bullmastiff-stimulated leukocyte response microarray dataset. This resulted in a list of 554 TSGs that were represented on the microarray. A small subset of these 554 genes, determined by manual annotation to be associated with lymphoma, was selected as candidate genes for further analysis.

Gene set enrichment analysis and functional annotation clustering. Gene sets within the TSG subset significantly enriched in activated leukocytes were identified using gene set enrichment analysis. Three gene set collections downloaded from the Molecular Signatures Database were used, including hallmark gene sets (50 gene sets), gene ontology (GO) gene sets (1454 gene sets), and oncogenic signature gene sets (189 gene sets). Gene sets with a nominal P value of <0.05 and an FDR q-value of <0.25 following 1000 permutations were classified as significantly enriched. The 20 most upregulated and downregulated TSGs were analyzed for functional annotation clustering using the Database for Annotation, Visualization and Integrated Discovery. A group enrichment score cutoff of 1.3 (Expression Analysis Systematic Explorer (EASE) = 0.05) was used to denote biological significance.

Cluster analysis. Cluster analysis of microarray data was performed on all TSGs annotated from the microarray as well as a separate analysis of the 20 most downregulated and upregulated genes, by rank. Separate cluster analyses were performed on TSG in hallmark gene sets significantly enriched with activated cells and genes known to be associated with lymphoma. Microarray expression data were input using R-statistical package and outputs generated through an integrated cluster analysis and display program, Heatmap (https://cran.r-project.org/web/packages/gplots/index.html). Additional annotations were sourced from Heatplus.

Quantitative reverse transcription PCR. Primers for candidate genes were designed using the online Primer 3 Plus software. Canine DNA sequences were obtained from GenBank at NCBI. Ensembl was used to visualize gene structure and assist in design around the intron–exon boundaries. Each primer was designed to generate an amplicon of between 100 and 200 bp and spanned at least one intron to avoid amplification
of any residual genomic DNA (Table 1). Primers were commercially manufactured (Thermo Fisher Scientific). Canine RNA samples (1 µg) were reverse transcribed into cDNA using the GoScript Reverse Transcription System (Promega) with oligo-dT primers, and the following protocol: denaturation at 70 °C for five minutes, extension at 42 °C for one hour, and inactivation at 70 °C for 15 minutes. Resulting cDNA was used as template for PCR under the following cycling conditions: activation cycle at 95 °C for five minutes, followed by 35 cycles at 94 °C for one minute, at 60°C for one minute, and at 70 °C for one minute. PCR products were initially visualized on a 2% agarose gel to confirm amplification of correct amplicons.

Relative gene expression for a subset of six samples (SM5, SM6, SM9, SM13, SM14, and SM16) was determined using qRT-PCR and a SYBR green mastermix (QuantiFast; Qiagen) with the same protocol as described in the preceding section and monitored via real-time thermal cycler (Rotor-Gene 6000; Qiagen). Each sample was run in duplicate. GAPDH was included as an endogenous control gene. RNA from the remaining five dogs was unavailable for use in qRT-PCR.

The delta–delta Ct method was used to estimate relative transcript levels for each gene. All Ct values were normalized against a GAPDH reference gene. The level of gene expression in stimulated samples relative to unstimulated samples was then calculated by 2−ΔΔCt, giving a relative expression value for each gene.

Results

Identification of TSGs. Of the 637 genes identified in the TSG database, a total of 554 TSGs were identified as being expressed in leukocytes. TSGs p53, p21 (CDKN1A), p27 (CDKN1B), p18 (CDKN2C), p19 (CDKN2A), and p15 (CDKN2B) were identified as a subset of candidate genes for further analysis based on their known association with lymphoma based on human and canine literature. p16 and p14 were not annotated within the microarray but were included on the basis of previous research in canine lymphoma.

Gene set enrichment analysis and functional annotation. A total of 49 gene sets consisting of TSG subsets were significantly enriched in activated leukocytes (Table 2). These included 3 upregulated hallmark gene sets, TNFA signaling via NF-kB, p53 signaling, and mTORC1 signaling, and 46 GO gene sets. No oncogenic signaling gene sets were significantly enriched in activated cells. A total of five biologically significant functional annotation clusters were identified in the 20 TSG subsets, and clusters identified were associated with cellular response to stimulation, ion binding, regulation of I-kappaB kinase/NF-kappaB cascade, negative regulation of cell proliferation, and regulation of leukocytes (enrichment scores 2.3, 2.01, 1.96, 1.96, and 1.39, respectively).

Cluster analysis. Cluster analysis demonstrated the variation in expression of TSGs across all samples. Clustering based on all 554 TSGs showed no distinguishable pattern of expression between stimulated and unstimulated samples (data not shown). However, it was clear that stimulation had a notable effect on expression of subsets of TSG in these dogs. A subset consists of 10 most downregulated genes, including KCNN6, TGFB2, TRIME13, RASSF2, KLF6, RBM5, DIRAS1, DOK1, CAPG, and COLA4A3, and 10 most upregulated genes, including EGR1, EGR2, PLK2, PAWR, PRKCI, BTG2, TNFAIP3, ZFP36, and FABP3. Cluster analysis of these genes revealed distinct clustering of expression patterns between stimulated and unstimulated samples (Fig. 1). A distinct pattern was also present in a subset of 17 TSGs from three hallmark gene sets, stimulated samples clustering separately to resting samples (Fig. 2).

Cluster analysis of the candidate TSGs showed a less distinctive pattern of expression (Fig. 3). Seven dogs showed consistent upregulation of p18, p19, p21, and p27 in active cells highlighting a regulated response following activation in these individuals. Expression of p53 and p15 showed more variation across dogs and activation states. Variation in expression patterns between dogs was evident, and the majority of genes in the subset downregulated in active samples from dogs SM1, SM10, and SM17.

Analysis by qRT-PCR. Primers were designed for seven different genes, including p18, p19, p21, p27, p53, p14, and p15. Primers designed for the p16 gene failed to amplify the targeted region despite multiple designs, modification, and optimization. Analysis of differential gene expression between stimulated and unstimulated samples was expressed as relative fold change. DE based on qRT-PCR was compared with values from microarray analysis, shown as a comparative histogram for all genes except for p14, which was not annotated within

Table 1. List of TSG primers used for qRT-PCR.

| GENE NAME | PRIMERS (FORWARD/REVERSE) | SEQUENCE 5’-3’ |
|-----------|---------------------------|----------------|
| p14 (CDKN2A) | Forward | TGGTGTAAACGTAGTGAGGAG |
| Reverse | CTTCTGACAGCAGCTGGT |
| p15 (CDKN2B) | Forward | GATCCCCACGGTAGCAACAG |
| Reverse | CTTCTGACCAGCAGCTGGT |
| p16 (CDKN2A) | Forward | AGACGATTCAGAGGCCCTTC |
| Reverse | GATTCAGGTCTAGTAGGGG |
| p18 (CDKN2C) | Forward | GGGGGCAACAGGCAACATTAC |
| Reverse | GAGGTGCTAATCCCGATTG |
| p19 (CDKN2A) | Forward | GCTGACAGGTCTAGTGTTG |
| Reverse | CCAATGTCACAGGATGCCA |
| p21 (CDKN1A) | Forward | CAGACGACGTACAGCAGTTC |
| Reverse | CAAGCTTACGAAATGAGACC |
| p27 (CDKN1B) | Forward | CAGAGGACACACACTTGTTAGA |
| Reverse | AGTGAGGAGCAGCGCTAAGA |
| p53 (TP53) | Forward | CAGTTGTGTTGTGGCTTTAG |
| Reverse | TCATCACCCCTGGAAGACTCC |
Table 2. Gene sets significantly enriched with activated leukocytes.

| GENE SET NAME                                                                 | NOMINAL P-VALUE | FDR Q-VALUE |
|--------------------------------------------------------------------------------|-----------------|-------------|
| Hallmark TNFA signaling via NFKB                                               | 0.006           | 0.127       |
| Hallmark mTORC1 signaling                                                     | 0.034           | 0.210       |
| Hallmark p53 pathway                                                          | 0.004           | 0.246       |
| Positive regulation of biological process                                     | 0.002           | 0.096       |
| Inflammatory response                                                         | 0.008           | 0.096       |
| Positive regulation of cellular metabolic process                             | 0.012           | 0.103       |
| Negative regulation of transcription                                           | 0.014           | 0.103       |
| Positive regulation of cellular process                                       | 0.004           | 0.105       |
| Macromolecule catabolic process                                                | 0.004           | 0.106       |
| Biopolymer catabolic process                                                  | 0.004           | 0.110       |
| Regulation of nucleobasenucleosidenucleotide and nucleic acid metabolic process| 0.004           | 0.110       |
| Positive regulation of metabolic process                                      | 0.012           | 0.111       |
| Positive regulation of developmental process                                  | 0.014           | 0.115       |
| Negative regulation of transcription from RNA polymerase ii promoter          | 0.012           | 0.116       |
| Protein dimerization activity                                                 | 0.008           | 0.118       |
| Transcription from RNA polymerase ii promoter                                  | 0.014           | 0.118       |
| Biopolymer metabolic process                                                  | 0.004           | 0.119       |
| Regulation of transcription                                                   | 0.014           | 0.119       |
| Response to wounding                                                          | 0.016           | 0.122       |
| Positive regulation of transcription                                           | 0.006           | 0.122       |
| Regulation of metabolic process                                                | 0.012           | 0.133       |
| Positive regulation of nucleobasenucleosidenucleotide and nucleic acid metabolic process | 0.006 | 0.135 |
| Transcription                                                                 | 0.019           | 0.135       |
| Negative regulation of RNA metabolic process                                  | 0.010           | 0.136       |
| Regulation of cellular metabolic process                                       | 0.012           | 0.138       |
| Negative regulation of nucleobasenucleosidenucleotide and nucleic acid metabolic process | 0.010 | 0.143 |
| Negative regulation of transcription DNA dependent                            | 0.010           | 0.155       |
| Cellular macromolecule catabolic process                                      | 0.012           | 0.170       |
| Protein homodimerization activity                                              | 0.020           | 0.172       |
| Regulation of gene expression                                                  | 0.002           | 0.180       |
| Apoptosis go                                                                  | 0.020           | 0.183       |
| Anti apoptosis                                                                | 0.036           | 0.186       |
| G1 s transition of mitotic cell cycle                                         | 0.041           | 0.187       |
| Programmed cell death                                                         | 0.020           | 0.187       |
| DNA binding                                                                   | 0.013           | 0.189       |
| DNA metabolic process                                                         | 0.006           | 0.191       |
| Protein domain specific binding                                                | 0.029           | 0.191       |
| Negative regulation of cellular process                                       | 0.012           | 0.192       |
| Transcription factor activity                                                  | 0.038           | 0.195       |
| Positive regulation of transcription from RNA polymerase ii promoter          | 0.044           | 0.195       |
| Nucleus                                                                       | 0.002           | 0.196       |
| Regulation of programmed cell death                                           | 0.002           | 0.202       |
| Negative regulation of biological process                                     | 0.014           | 0.204       |
| Nuclear lumen                                                                 | 0.046           | 0.206       |

(Continued)
the microarray data (Fig. 4). All genes were consistently upregulated in stimulated samples relative to unstimulated, with the exception of p53, once again indicating a regulated response after stimulation in 6 of the 11 dogs.

**Discussion**

The phenotype of lymphomas derived from mature lymphocytes may vary considerably but is usually indicative of an activated lymphocyte state. Identification of TSG expression profiles associated with an activated lymphocyte phenotype in dogs can be used to distinguish between normal and pathogenic expression profiles. Here, we isolated cells from blood, considered to represent a naïve phenotype, and stimulated them in vitro. Overall, 554 genes assembled from a human TSG database were annotated in a canine microarray dataset. Analysis of all genes simultaneously revealed no clustering of gene expression between stimulated and unstimulated samples. Conversely, gene subsets from this TSG dataset including genes sets from

**Table 2. (Continued)**

| GENE SET NAME                  | NOMINAL P-VALUE | FDR Q-VALUE |
|--------------------------------|-----------------|-------------|
| Protein complex                | 0.024           | 0.208       |
| Regulation of binding          | 0.060           | 0.213       |
| Macromolecular complex         | 0.024           | 0.213       |
| Catabolic process              | 0.043           | 0.229       |
| Cellular catabolic process     | 0.043           | 0.234       |

**Figure 1.** Cluster analysis of top 10 most downregulated and top 10 most upregulated TSG in stimulated and unstimulated cells. Clustering of samples is shown across the top of the image. Samples denoted with the “P” suffix were stimulated with PHA. Expression level increases from green (downregulated) to red (upregulated). Sample SM4P has no paired unstimulated sample.
Molecular Signatures Database did distinguish variation in gene expression of stimulated and unstimulated samples.

The lack of any distinctive clustering pattern in the analysis of the entire set of TSG suggests that TSG expression responded variably to the stimulation protocol used in this study. This method induces a relatively low level of activation in the immediate-early period of gene responses. The lack of distinctive patterns is perhaps not surprising given the large number of genes in the total group. A distinct pattern of expression between stimulated and unstimulated cells could be seen in a subset of 20 TSG genes consisting of 10 most upregulated and 10 most downregulated genes. Functional annotation of this TSG subset highlighted the role of these genes in cellular response pathways, regulation of cell death and apoptosis, differentiation and activation of leukocytes, and negative regulation of cell proliferation. Distinct expression patterns of genes from similar functional groups following activation have been identified in both humans and mice. These genes highlight that under- and overrepresented genes in an activated phenotype may be useful for discrimination.

Expression profiles of TSG within significantly enriched gene sets provide additional candidates for distinguishing between activation states. TSG associated with GO gene sets, including regulation of cellular metabolism, transcription, catabolic processes, apoptosis, and inflammatory responses, were significantly enriched in activated cells highlighting the importance of these biological functions in leukocyte activation. Most notable are the enriched hallmark gene sets consisting of three well known cell regulation pathways. The p53 pathway identified is important for cellular response to stress signals and initiation of cell cycle arrest and apoptosis. An NF-kB regulatory pathway was also enriched in activated cells, important in innate immunity and inflammatory response. Activation of target genes within this pathway can lead to stimulation of lymphocyte proliferation and inhibition of cell death and apoptosis. The third hallmark gene set, the mTORC1 signaling pathway, is commonly activated during T-cell activation and has been shown to regulate cell growth and proliferation. Mutations to TSG regulating the mTOR pathway have been associated with human disease, inactivation of downstream targets leading to upregulation of vascular endothelial growth factor (VEGF) expression and promotion of tumor angiogenesis, supporting the use of mTOR as a target in cancer therapies.

**Figure 2.** Cluster analysis of TSG in hallmark gene sets significantly enriched with stimulated cells. Samples denoted with the “P” suffix were stimulated with PHA. Expression level increases from green (downregulated) to red (upregulated). Sample SM4P has no paired unstimulated sample.
of these gene sets in regulating lymphocyte activation, proliferation, and potentially cancer development highlight them as new targets for expression profiling to develop a more extensive activation phenotype.

Genes selected as candidates based on known association with lymphoma in human, canine, and mouse studies included p15, p18, p19, p21, p27, and p53. Activation had a marked effect on four of these genes, p18, p19, p21, and p27, resulting in a distinct pattern of gene expression in the microarray analysis in seven dogs. This may reflect the interrelated functional role of these genes in regulating cell cycle. There is some clustering of these genes within the analysis. Some of these genes belong to the cyclin-dependent kinase inhibitors. Members of the INK4 family encode the genes represented by the cluster, including p15, p18, and p19. These genes are involved in the inhibition of cyclin-dependent kinases 4 and 6, which are critical for phosphorylation of the retinoblastoma protein in regulating cell cycle progression. The p21 and p53 gene expression profiles are also clustered; p21 is also a regulator of cyclin-dependent kinases and is in turn regulated by expression of p53. The other notable inclusion, p27, is encoded by the CDKN1B gene. It is also a potent regulator of CDK2.

Primers for p14, p15, p18, p19, p21, p27, and p53 showed consistent amplification of target products and will be useful for further canine studies. Amplification of p16 was not successful in this study despite repeated attempts and redesign. Primers for canine p16 have been described, based on a design within the third exon, but these do not distinguish any residual DNA in samples. The results of qRT-PCR were comparable with those of microarray but across a greater dynamic range and only within the six dogs used. An exception was p53, which was downregulated substantially in stimulated samples when compared to microarray data. The microarray did not have any probes representing p14, so it could not be compared. There have been a number of developments toward specialized arrays based on a subset of genes that are significant in cancer analysis, including canine cancer.

When analyzed as a group, the pattern of expression of candidate TSG discriminated the activation status of leukocytes, that is, between stimulated and unstimulated samples, within six dogs. The expression pattern, however, failed to
discriminate between the remaining five dogs. Potential still exists for these genes to be used as candidates for distinguishing between a normal leukocyte activation phenotype and a pathogenic phenotype in lymphoma. Human studies have described differential patterns of expression for p14, p15, p16, p21, p27, and p53 from patients with varying forms of lymphoma. In addition, the CDKNs p18 and p19 have been linked to a variety of other cancers in humans but have yet to be extensively studied in the context of lymphoma. All of the candidate genes included in this study have been deleted in mice and resulted in increased susceptibility to lymphoma.

The results presented here suggest that TSG subsets can be used to characterize an activated leukocyte phenotype in dogs, which may provide a test set for further analysis of canine lymphoma samples. Expression patterns within TSG subsets were able to distinguish between activated and resting cells in the individuals included in the study; however, these need to be validated in a larger sampling of dogs. The ability to distinguish between a normal activation phenotype and a pathogenic phenotype associated with lymphoma development, using the candidate genes and TSG subsets identified in this study, offers the potential for use in diagnostic testing.

Acknowledgment

We thank the owners of dogs that consented to the study and the valuable cooperation of the Bullmastiff Club of NSW.

Author Contributions

Conceived and designed the experiments: PW, SM. Analyzed the data: JD, SM, RT, PW. Wrote the first draft of the manuscript: JD, SM, PW. Contributed to the writing of the manuscript: JD, SM, RT, PW. Agree with manuscript results and conclusions: JD, SM, RT, PW. Jointly developed the structure and arguments for the paper: JD, SM, RT, PW. Made critical revisions and approved final version: SM, PW. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163–208.
2. Hämé DA, Freeman TC. Transcriptomic analysis of mononuclear phagocyte differentiation and activation. Immunol Rev. 2014;262(1):74–84.
3. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.
4. Liu DL., Xiong H, Ellis AE, et al. Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. Cancer Res. 2014;74(18):5045–56.
5. Dobson JM, Samuel S, Milletone H, Rogers K, Wood JLN. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract. 2002;43(1):240–6.
6. Merlo DF, Rossli L, Pellegrino C, et al. Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa, Italy. J Vet Intern Med. 2008;22(4):976–84.
7. Modiano JF, Breen M, Burnett RC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005;65(13):5654–61.
8. Beaver LM, Strottner G, Klein MK. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006–2008). J Am Vet Med Assoc. 2010;237(9):1052–5.
9. Modiano JF, Breen M. Genetics of hematopoietic neoplasia. In: Weiss DJ, Wardrop KJ, eds. Schalm’s Veterinary Hematology. 6 ed. Wiley-Blackwell Publishing Ltd., Hoboken, NJ, USA; 2010:433–8.
10. Macleod K. Tumor suppressor genes. Crit Rev Oncog Denovo. 2000;10(1):81–93.
11. Taneja P, Zhu S, Maglic D, Fry EA, Kendig RD, Inoue K. Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol. 2011:5:235–57.
12. Yamada Y, Kamihira S. Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma. 2005;46(11):1553–3.
13. Fournier SP, Thomas R, Jubala CM, et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin’s T-Cell lymphoma. Vet Pathol. 2007;44(4):467–78.
14. Thomas R, Smith KC, Ostrander EA, Galibert F, Breen M. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer. 2003;89(1):1530–7.
15. Nasir L, Angély DJ. Mutational analysis of the tumor suppressor gene p53 in lymphosarcoma in two bull mastiffs. Vet Res. 1999;145(1):23–4.
36. Mortlock SA, Wei J, Williamson P. T-cell activation and early gene response in dogs. *PLoS ONE.* 2015;10(3):e0121169.

37. Iriarrazy RA, Hobbs B, Collin P, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics.* 2003;4(2):249–64.

38. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. *Statistical Applications in Genetics and Molecular Biology.* 2004;3(1):1–25

39. Benjamin Y, Hochberg Y. Controlling the false discovery rate – a practical and powerful approach to multiple testing. *J R Stat Soc Series B Methodol.* 1995;57(1):289–300.

40. Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. *Nucleic Acids Res.* 2013;41(Database issue):D970–6.

41. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545–50.

42. Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet.* 2003;34(3):267–73.

43. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc.* 2009;4(1):44–57.

44. Untergasser A, Cutcutache I, Koressaar T, et al. Primer3—new capabilities and interfaces. *Nucleic Acids Res.* 2012;40(15):e115.

45. Livek KJ, Schnirring TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods.* 2001;25(4):402.

46. Teague TK, Hildeman D, Kedl RM, et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. *Proc Natl Acad Sci U S A.* 1999;96(22):12691–6.

47. Ellison LW, Palmer RE, Maki RG, et al. Cascades of transcriptional induction during human lymphocyte activation. *Eur J Cell Biol.* 2001;80(5):321–8.

48. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. *Eur J Cell Biol.* 2010;90(3):1269–76.

49. Rathnall JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. *Cell.* 2002;109(2 suppl 1):S97–107.

50. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. *Oncogene.* 2005;24(17):2899–908.

51. Kasten N, Bross R, Oren M, Rutter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. *Genes Cancer.* 2011;2(4):466–74.

52. Stracquadanio G, Wang XT, Wallace MD, et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes. *Nat Rev Cancer.* 2016;16(4):251–65.

53. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. *Science.* 1996;274(5288):782–4.

54. Karin M, Cao Y, Greten FR, Li Z-W. NF-κB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer.* 2002;2(4):301–10.

55. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tissu C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Nat Cell Biol.* 2004;6(1):390–6.

56. Laplaute M, Salatini DM. mTOR signaling at a glance. *J Cell Sci.* 2009;122(20):3589–94.

57. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. *Curr Opin Pharmacol.* 2003;3(4):371–7.

58. Tee AR, Blenis J. mTOR, translational control and human disease. *Semin Cell Dev Biol.* 2005;16(1):29–37.

59. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. *Front Mol Neurosci.* 2011;4:51.

60. Hatta Y, Koehler HP. Role of tumor suppressor genes in the development of adult T-cell leukemia/lymphoma (ATLL). *Leukemia.* 2002;16(6):909–85.

61. Fujisawa-Igarashi A, Goto-Koshino Y, Mochinuki H, et al. Simultaneous inactivation of the p16, p15 and p14 genes encoding cyclin-dependent kinase inhibitors in canine T-lymphoid tumor cells. *J Vet Med Sci.* 2013;75(6):733–42.

62. Mariotti ET, Premanandan C, Lorch G. Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation. *BMC Vet Res.* 2014;10:19.

63. Tamburini BA, Phang TL, Fosmire SP, et al. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. *BMC Cancer.* 2010;10:619.

64. Davies C, Hagarth IA, Dietrich PA, et al. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. *J Biol Chem.* 2011;286(43):37639.

65. Laharanne E, Chevet E, Idrissi Y, et al. CDKN2A C-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. *Med Pathol.* 2011;24(10):457–62.

66. Kohno T, Yamada Y, Iwara M, et al. Inactivation of p14 ARF as a key event for the progression of adult T cell leukemia/lymphoma. *Leuk Res.* 2007;31(12):1625–32.

67. Gazzola A, West P, Zinzani PL, et al. CDKN1B/p27 expression in peripheral T-cell lymphoma not otherwise specified. *J Clin Pathol.* 2011;64(1):83–7.

68. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. *Leukemia.* 1998;12(6):845–59.

69. Williams ME, Whitefield M, Swedlow SH. Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. *Ann Oncol.* 1997;8(suppl 2):71–3.

70. Bai F, Pei X-H, Godfrey VL, Xiong Y. haploinsufficiency of p18(INK4c) sensitizes mice to carcinoma-induced tumorigenesis. *Mol Cell Biol.* 2003;23(4):1269.